Orbactiv is owned by Melinta Therap.
Orbactiv contains Oritavancin Diphosphate.
Orbactiv has a total of 3 drug patents out of which 0 drug patents have expired.
Orbactiv was authorised for market use on 06 August, 2014.
Orbactiv is available in powder;intravenous dosage forms.
Orbactiv can be used as treatment of bacterial skin and skin structure infections using a single dose, treatment of bacterial skin and skin structure infections.
Drug patent challenges can be filed against Orbactiv from August, 2023.
The generics of Orbactiv are possible to be released after 16 July, 2035.
|Patent Number||Company||Patent Title||Patent Expiry||Activity Alert|
|These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).|
|US8420592||MELINTA THERAP||Methods of treatment using single doses of oritavancin|| |
(6 years from now)
|US9682061||MELINTA THERAP||Methods of treating bacterial infections using oritavancin|| |
(7 years from now)
|US9649352||MELINTA THERAP||High purity oritavancin and method of producing same|| |
(12 years from now)
|New Chemical Entity Exclusivity (NCE)||Aug 6, 2019|
|Generating Antibiotic Incentives Now (GAIN)||Aug 6, 2024|
NCE-1 date: August, 2023
Market Authorisation Date: 06 August, 2014
Treatment: Treatment of bacterial skin and skin structure infections using a single dose; Treatment of bacterial skin and skin structure infections
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic